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Introduction and Background
Colorectal cancer (CRC) is among the most common 
human malignancies and remains a leading cause of 
cancer-related morbidity and mortality [1]. Colorectal 
cancer is the third most common cancer in the UK: its 
incidence increases with age, the median age at diagnosis 
being over 70 years. 
Colorectal carcinogenesis is a multistep process char-
acterized by molecular and cellular alterations that result 
in an identifiable precursor lesion – the adenomatous 
polyp. The transition from normal mucosa to adenoma 
and its subsequent progression to carcinoma are pro-
tracted events that offer opportunities for preventive in-
terventions. Suppression or reversal of the carcinogenic 
process in the colorectum with nonpharmacologic or 
pharmacologic agents, i.e. chemoprevention, is an area 
of considerable research interest and activity [1].
Discussion
Chemoprevention is defined as the employment of 
drugs or natural compounds to prevent the develop-
ment of benign or malignant tumors [2]. Epidemio-
logical studies have shown that individuals reporting a 
regular intake of aspirin and other non-steroidal anti-
inflammatory drugs have a reduced risk of developing 
colorectal polyps and cancer.
There have been several large epidemiological and 
observational studies to evaluate the possible protective 
effects of >200 agents [3]. Some studies have showed 
that a regular and continued use of non-steroidal 
anti-inflammatory drugs (NSAIDs), predominantly of 
aspirin, is associated with significant reductions in both 
colorectal adenoma and carcinoma incidence. NSAIDs 
were first shown to be effective in patients with familial 
adenomatous polyposis (FAP). Subsequent randomized 
trials in FAP have demonstrated that sulindac and the 
selective cyclooxygenase-2 (COX-2) inhibitor, celecox-
ib, can significantly regress the existing adenomas, and 
resulted in the Food and Drug Administration (FDA) 
approval of celecoxib for an adjunctive management of 
these patients.
Apoptosis in the colonic epithelium appears to be 
progressively inhibited during colonic carcinogenesis 
[4]. Evidence is now growing that the induction of 
apoptosis is one of the ways in which NSAIDs prevent 
cancer, and they may well exert their chemopreventive 
effects in the colon by restoring a normal frequency of 
apoptosis in the colonic mucosa.
The selective COX-2 inhibitor, celecoxib, at a dose 
of 400 mg twice daily, has been shown to reduce the 
mean number of polyps by 28% in patients with the rare 
genetic disorder – familial adenomatous polyposis [5]. 
This has led to the approval by the US Food and Drug 
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Administration of the use of celecoxib for the reduction 
of polyp numbers in patients with familial adenomatous 
polyposis (together with endoscopic surveillance or 
surgery). Studies are currently ongoing on the effective-
ness of COX-2 inhibitors in preventing the recurrence 
of sporadic colorectal adenomas, either when used as a 
sole therapy or in combination with other agents [7].
Pending the expected release of results from several 
phase III trials in the near future, chemoprevention for 
colorectal cancer can only be practically considered in 
the very-high-risk population like those with familial 
adenomatous polyposis and ulcerative colitis, in con-
junction with surveillance colonoscopy.
A number of studies have found a reduction in the 
risk of colorectal adenomas and cancer with a long-term 
dietary supplementation with folic acid.
Women who had regularly taken multivitamins 
(containing folic acid) for at least 15 years showed the 
greatest reduction in the risk of developing colonic 
cancer [6]. Nevertheless, there are no prospective studies 
to support the idea that a long-term multivitamin use 
influences the risk of rectal cancer. Folic acid is currently 
being investigated in prospective trials to further evalu-
ate its potential efcacy as a chemopreventive agent.
Calcium, vitamin D, and some minerals (gamma-
tocopherol and selenium) have protective effects, and 
daily exercise for > or =30 min results in a significant 
decrease of risk.
Diets high in animal fats and red meat have been 
found to be associated with an increased risk of colonic 
adenomas and colorectal cancer. Although the exact 
mechanism is unclear, it may be related to increased 
concentrations of secondary bile acids within the colon, 
which may increase cell proliferation in the colonic mu-
cosa and have been found to be carcinogenic in animal 
models. Recently, a higher calcium intake was found to 
be associated with a significantly lower risk of distal but 
not proximal colonic cancer.
It is estimated that up to 80% of colorectal cancers 
may be preventable by dietary change. As an adjunct to 
chemopreventive agents, experiments in animals appear 
to support the use of low-fat diet regimes (preferably 
with higher intakes of omega-3 fatty acids) as a desirable 
approach to the primary prevention of colorectal cancer 
in the general population. High-galactose fruit and veg-
etable fibers, selenium and folic acid supplementation, 
and low-fat diets may well be the dietary interventions 
that could reduce the risk of colorectal cancer [8].
The risk of developing colorectal cancer is influenced 
by several acquired risk factors, including environmen-
tal exposures and the comorbid medical conditions 
that are partially genetic in nature (165). Acquired 
risk factors include the following categories: 1) dietary 
factors, 2)  lifestyle factors, 3) side-effects of medical 
interventions, and 4) comorbid medical conditions. 
The dietary factors that potentially increase the risk of 
CRC include low fruit, vegetable, or fiber intake, high 
red meat or saturated fat consumption, and exposure 
to caffeine or alcohol. Of these factors, the significance 
of low fruit, vegetable, and fiber intake has been called 
into question because of contradictory results from large 
observational studies and negative results from random-
ized trials. The association of high red meat or saturated 
fat consumption with increased CRC risk is supported 
by the preponderance of observational data. Lifestyle 
factors include the lack of exercise, alcohol drinking, 
and smoking. The association between inflammatory 
bowel disease and CRC is well established, and it forms 
the basis for widely adopted colonoscopic surveillance 
recommendations from national medical organizations.
Conclusions
Further research would be useful to investigate the 
longer-term risk–benefit balance for those potentially 
effective chemopreventive agents; for example, whether 
there is a dose level that gives a significant benefit with-
out  unacceptable toxicity, what treatment durations 
are required, whether an effect on CRC can be demon-
strated, and for how long the benefits are maintained 
after the intervention is stopped. Larger studies that 
follow up participants over long time periods (e.g., 20 
years) and assess CRC incidence as an outcome would 
be valuable. Also, studies in which participants take 
these interventions for longer durations (e.g., 10 years 
or more) would be valuable to assess the risk–benefit 
balance associated with long-term chemoprevention. 
Within the general population, even for studies with 
a relatively short treatment duration, a long-term follow-
up is essential if the primary outcome is CRC incidence.
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